benzonidazole has been researched along with Sepsis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carnovale, CE; Catania, VA; de Luján Alvarez, M; Francés, DE; Lambertucci, F; Martín-Sanz, P; Motiño, O; Quiroga, AD; Rigalli, JP; Ronco, MT; Villar, S | 1 |
| Carnovale, C; Francés, D; Manarin, R; Revelli, S; Ronco, MT; Serra, E | 1 |
2 other study(ies) available for benzonidazole and Sepsis
| Article | Year |
|---|---|
Benznidazole, the trypanocidal drug used for Chagas disease, induces hepatic NRF2 activation and attenuates the inflammatory response in a murine model of sepsis.
Topics: Animals; Antioxidants; Chagas Disease; Disease Models, Animal; Down-Regulation; Inflammation; Liver; Male; Mice; Mice, Inbred C57BL; NF-E2-Related Factor 2; Nitroimidazoles; Oxidative Stress; Sepsis; Toll-Like Receptor 4; Trypanocidal Agents | 2017 |
Benznidazole treatment attenuates liver NF-κB activity and MAPK in a cecal ligation and puncture model of sepsis.
Topics: Animals; Cecum; Disease Models, Animal; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Exudates and Transudates; Gene Expression Regulation; Leukocyte Count; Ligation; Liver; Mice; Mice, Inbred C57BL; Mitogen-Activated Protein Kinases; NF-kappa B; Nitric Oxide Synthase Type II; Nitroimidazoles; p38 Mitogen-Activated Protein Kinases; Punctures; RNA, Messenger; Sepsis; Time Factors; Tumor Necrosis Factor-alpha | 2011 |